Sanofi Global Health Unit

The Sanofi Global Health Unit (GHU) is a self-sustained nonprofit unit aiming at providing access to affordable and sustainable healthcare to the 40 poorest countries in the world. The GHU will increase access to essential medicines within the company’s portfolio, support healthcare strengthening and help accelerate innovative care models.
  • Improving access to affordable quality treatments
  • Strengthening health systems and care delivery to patients
  • Building impactful multisectoral partnerships to act as a catalyst
  • Scale-up pioneer healthcare delivery ventures

Sanofi Global Health is a newly formed nonprofit unit within Sanofi that sets out to improve the lives of underserved populations through innovative inclusive healthcare models and partnerships, delivering sustainable impact.

In July 2022, Sanofi Global Health launched its own brand, the Impact® brand, at access price. Leveraging the company’s global footprint and vast portfolio of medicines, the Impact® brand will increase access to 30 medicines considered essential by the World Health Organization (WHO) for patients in 40 lower-income countries (LICs).

The Impact® brand covers a wide range of therapeutic areas, including diabetes, cardiovascular disease, tuberculosis, and cancer. One of the treatments that this initiative seeks to make available at accessible prices for lower-income countries are analog insulins, furthering Sanofi’s ambition to improve diabetes care for 300,000 insulin-dependent patients by 2030 and reach 20 times more patients than those receiving diabetes care in 2021.

Besides improving access to essential medicines, it intends to support health system strengthening efforts including building cancer care capabilities through specific trainings as well as invest in local entrepreneurs’ inclusive businesses to scale up financially viable care solutions.

By shaping transformative healthcare models and reaching the most vulnerable, the program aims to treat over 2 million patients by 2030.

Sanofi has also announced an Impact Fund with an up to 25€ million commitment that will enable startup companies and entrepreneurs to accelerate delivery of sustainable healthcare models.

On top of the financial contributions, the Fund will also provide technical assistance and mentorship through employee engagement to expand support to local inclusive businesses and scale-up pioneer healthcare delivery ventures with potential to be sustainable overtime.

To achieve these goals the program will also fund the training of healthcare professionals to increase cancer care capabilities and will invest in sustainable healthcare systems for better delivery of care.

Results and milestones
  • On 07 April 2021, Sanofi announced the Sanofi Global Health Unit.
  • On 04 July 2022, Sanofi launched the Impact® brand & Impact Fund.
  • The Impact Glargine U100 will be the first analog insulin to be submitted for WHO pre-qualification.
Geographic Reach
  • Global Commitment
Disease Area
  • Infectious and Parasitic Disease
  • Non-communicable diseases
See Disease Areas